Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of “Buy” by Analysts

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has earned a consensus recommendation of “Buy” from the ten ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $25.2857.

Several research analysts have recently issued reports on the stock. HC Wainwright lowered their price target on shares of Day One Biopharmaceuticals from $36.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Needham & Company LLC lowered their price target on shares of Day One Biopharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Piper Sandler assumed coverage on shares of Day One Biopharmaceuticals in a report on Monday, August 18th. They set an “overweight” rating and a $25.00 price target for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Day One Biopharmaceuticals in a report on Wednesday, October 8th. Finally, Zacks Research upgraded shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 13th.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ:DAWN opened at $7.36 on Friday. The company has a fifty day moving average of $7.22 and a 200-day moving average of $6.91. The company has a market capitalization of $753.88 million, a PE ratio of -7.75 and a beta of -1.26. Day One Biopharmaceuticals has a 52-week low of $5.64 and a 52-week high of $16.76.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.06. The company had revenue of $33.91 million during the quarter, compared to the consensus estimate of $35.55 million. Day One Biopharmaceuticals had a negative net margin of 50.63% and a negative return on equity of 19.01%. On average, equities analysts forecast that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Charles N. York II sold 4,106 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $6.77, for a total value of $27,797.62. Following the completion of the sale, the chief financial officer directly owned 278,000 shares in the company, valued at $1,882,060. This represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Lauren Merendino sold 3,766 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $6.77, for a total value of $25,495.82. Following the completion of the sale, the insider owned 41,931 shares of the company’s stock, valued at $283,872.87. The trade was a 8.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,295 shares of company stock valued at $191,557. Company insiders own 6.20% of the company’s stock.

Institutional Trading of Day One Biopharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. increased its holdings in Day One Biopharmaceuticals by 44.5% in the second quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock valued at $48,000 after purchasing an additional 2,264 shares during the period. Entropy Technologies LP acquired a new stake in Day One Biopharmaceuticals in the second quarter valued at $67,000. Prudential Financial Inc. bought a new stake in Day One Biopharmaceuticals during the second quarter valued at $69,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Day One Biopharmaceuticals during the second quarter valued at $76,000. Finally, Quantbot Technologies LP bought a new stake in Day One Biopharmaceuticals during the first quarter valued at $82,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.